The Claim
In children and adolescents with functional abdominal pain or irritable bowel syndrome, open-label placebo administration is associated with a 53.3% reduction in the proportion of patients requiring rescue medication during the placebo period compared to the control period.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In children and adolescents with functional abdominal pain or irritable bowel syndrome, taking an open-label placebo led to a 53.3% lower rate of rescue medication use during the placebo period compared to the control period.
See the scientific wording
In children and adolescents with functional abdominal pain or irritable bowel syndrome, open-label placebo administration is associated with a 53.3% reduction in the proportion of patients requiring rescue medication during the placebo period compared to the control period, indicating a clinically meaningful decrease in symptom-driven pharmacological intervention.
When a child expects relief from a treatment—even if they know it's a sugar pill—their brain activates natural pain-blocking systems that calm the nerves in the gut, making stomach pain feel less intense and reducing the need for medicine.
What the research says
1 studyWhen kids with chronic stomach pain were told they were taking a sugar pill (and even told it was a placebo), they ended up needing fewer pain pills than when they took nothing. This shows that just believing in treatment—even knowing it’s fake—can help reduce symptoms.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.